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Background:  Hirustasin belongs to a class of serine protease inhibitors
characterized by a well conserved pattern of cysteine residues. Unlike the closely
related inhibitors, antistasin/ghilanten and guamerin, which are selective for
coagulation factor Xa or neutrophil elastase, hirustasin binds specifically to tissue
kallikrein. The conservation of the pattern of cysteine residues and the significant
sequence homology suggest that these related inhibitors possess a similar three-
dimensional structure to hirustasin.
Results:  The crystal structure of the complex between tissue kallikrein and
hirustasin was analyzed at 2.4 Å resolution. Hirustasin folds into a brick-like
structure that is dominated by five disulfide bridges and is sparse in secondary
structural elements. The cysteine residues are connected in an abab cdecde
pattern that causes the polypeptide chain to fold into two similar motifs. As a
hydrophobic core is absent from hirustasin the disulfide bridges maintain the
tertiary structure and present the primary binding loop to the active site of the
protease. The general structural topography and disulfide connectivity of
hirustasin has not previously been described.
Conclusion:  The crystal structure of the kallikrein–hirustasin complex reveals
that hirustasin differs from other serine protease inhibitors in its conformation and
its disulfide bond connectivity, making it the prototype for a new class of
inhibitor. The disulfide pattern shows that the structure consists of two domains,
but only the C-terminal domain interacts with the protease. The disulfide pattern
of the N-terminal domain is related to the pattern found in other proteins.
Kallikrein recognizes hirustasin by the formation of an antiparallel b sheet
between the protease and the inhibitor. The P1 arginine binds in a deep
negatively charged pocket of the enzyme. An additional pocket at the periphery
of the active site accommodates the sidechain of the P4 valine.
Introduction
The saliva of leeches contains a variety of protease inhibitors.
In order to maintain the liquid state of the ingested blood,
most of these inhibitors are directed against proteases that are
involved in blood coagulation; for example, hirudin specif-
ically inhibits thrombin [1], and decorsin inhibits platelet
aggregation by blocking fibrinogen binding to the platelet
receptor glycoprotein IIb-IIIa [2,3].
Recently, a 55 amino acid inhibitor, called hirustasin, has
been isolated from the leech Hirudo medicinalis [4]. It is able
to inhibit tissue kallikrein but not plasma kallikrein or
plasmin. Hirustasin is the first inhibitor of tissue kallikrein
that does not also inhibit plasma kallikrein. It has 27% and
32% sequence identity with the first and second domains,
respectively, of the 119 amino acid inhibitor antistasin,
which was originally isolated from the salivary glands of the
Mexican leech Haementeria officinalis [5]. Antistasin contains
10 disulfide bridges [6] and its primary structure shows a
twofold internal repeat, indicating that it has evolved by a
gene duplication event. Antistasin is a competitive, high-
affinity inhibitor of the serine protease coagulation factor
Xa, and is slowly cleaved at a single position during the
course of inhibition. A protein that is almost identical to
antistasin has been isolated from the giant Amazonian leech
Haementeria ghilianii and named ghilanten [7]. Hirustasin
differs from both antistasin and ghilanten in that it has no
inhibitory effect on factor Xa. Instead, it inhibits tissue
kallikrein, trypsin, chymotrypsin and neutrophil cathepsin
G. Hirustasin exhibits no apparent inhibitory activity against
elastases [4], but shares 51% sequence identity with the
human leukocyte and porcine pancreatic elastase-specific
inhibitor guamerin [8]; this 57 amino acid inhibitor has been
isolated recently from the Korean leech, Hirudo nipponia. 
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The inhibitor class comprising hirustasin, antistasin, ghi-
lanten and guamerin is characterized by the exact conser-
vation of the spacing of 10 cysteine residues within the
sequence of the protein [8]. This homology suggests the
existence of a common ancestor which diverged by gene
duplication and mutation events to produce a family of
inhibitors with different specificities: hirustasin, primarily
for tissue kallikrein; antistasin/ghilanten, specifically for
factor Xa; and guamerin, for elastase. Unlike the anticoag-
ulant antistasin, which, like hirudin, is essential to main-
tain the liquid state of ingested blood inside the leech 
[9], the biological functions of guamerin and hirustasin are
unknown.
Tissue kallikreins form a group of closely related serine
proteases that exhibit a narrow range of substrate speci-
ficities [10]. They belong to the peptidase family S1, also
known as the trypsin family, and to the glandular kallikrein
subfamily [11]. Tissue kallikreins catalyze the liberation 
of a biologically highly active kinin, kallidin or lysyl-
bradykinin, from ubiquitously occurring kininogens by
cleavage of a Met–Lys and Arg–Ser bond [12]. The tissue
kallikrein–kinin system contributes to the maintenance of
normal blood pressure and, using transgenic mouse models,
a direct link has recently been shown to exist between
kallikrein gene expression and changes in blood pressure
[13]. Porcine pancreatic kallikrein is by far the best studied
of the glandular kallikreins [14], and the crystal structure 
of this protease, both alone and complexed with aprotinin,
another kallikrein inhibitor, has been analyzed [15,16]. 
Here, we present the crystal structure of the complex
between hirustasin and porcine tissue kallikrein refined at
2.4Å resolution. This is the first three-dimensional (3D)
structure of a member of the inhibitor class to which hirus-
tasin belongs, and the first time that the interactions of 
a member of this class with the cognate protease have
been determined.
Results and discussion
Overall hirustasin topology
The two hirustasin–kallikrein complexes present in the
asymmetric unit (kallikrein 1, residues A16–B246; hirus-
tasin 1, residues I5–I52; kallikrein 2, residues X16–Y246;
hirustasin 2, residues J5–J52) have nearly identical confor-
mations. A pairwise comparison of the Ca atoms of the
protease and the inhibitor reveals root mean square (rms)
deviations values of 0.24Å and 0.36Å, respectively. The
larger rms deviation for the inhibitor is attributed to the
weak electron density of the N terminus of hirustasin 2.
Since this region is not stabilized by crystal packing inter-
actions, it is highly flexible. The N terminus of hirustasin
1 shows much stronger electron density, but nevertheless
possesses high B-factors. Except for the N terminus of
hirustasin 2, both complexes are well defined in the elec-
tron-density map. As the Ca rms deviation is in the range
of the estimated coordinate error, we consider the two
complexes to be identical. Figure 1 shows an omit-map 
of the primary binding loop in the first complex. The fol-
lowing discussion focuses on the first complex (residues
A16–B246 and I5–I52), because it possesses lower thermal
mobility.
Hirustasin is a monomeric serine protease inhibitor that
consists of 55 amino acid residues. In the crystal structure,
four N-terminal and three C-terminal residues are not
defined. The 48 residues that are seen in the electron-
density map fold into a brick-shaped structure with overall
dimensions of about 40×20×10Å3. There are 10 cysteine
residues involved in the formation of disulfide bridges
(Fig. 2a,b). The hirustasin structure is relatively compact,
but nevertheless can be subdivided into two domains.
The N-terminal domain (residues 5–23) contains disulfide
bridges Cys6–Cys17 and Cys11–Cys22, and the C-termi-
nal domain (residues 23–52) contains disulfide bridges
Cys24–Cys44, Cys29–Cys48 and Cys33–Cys50. Although
these domains are much smaller than the classical domains
[17], evidence for this subdivision comes from the Ca-
distance matrix (data not shown), the disulfide bonding
pattern (Fig. 3), and the similarity with structurally related
inhibitors (Fig. 4). The average distances for Ca atoms
within residues 5–23 and 23–52 are 9 Å and 11Å, respec-
tively, but the average distance for Ca atoms coming 
from the different parts is 19Å. As the average distance
between atoms from different parts is nearly twice as
large, these fragments can be considered as independent
domains. Residues 5–23 and 24–52 form domain N and
domain C, respectively.
According to the nomenclature of Benham and Jafri [18],
the cysteine residues are connected to form an abab cdecde
pattern. This pattern contains an internal repeat of two
sub-patterns. The abab and cdecde sub-pattern force the
connected chains to run parallel. The parallel arrangement
of residues 6–12 and 17–23 from domain N is repeated by
residues 24–33 and 44–50 from domain C. When the N-
and C-termini of a continuous polypeptide are running
parallel to each other, the resulting helical turn can be
either left- or right-handed. Surprisingly, both of the
twofolds in domains N and C are left-handed. The spacing
between subsequent disulfide bridges within a domain is
nearly identical (4–5 residues), but the number of residues
in the gap between cysteine residues from the same disul-
fide bridge differs. In domain N, this gap is 11 residues
long in both cases, whereas in domain C it varies between
17 and 20 residues. 
The structure of hirustasin contains few secondary struc-
tural elements. Only antiparallel b sheets are found and
no a helices. In domain N, residues 14–25 form a twisted
antiparallel b sheet and residues 6–9 and 12–15 form addi-
tional b turns. In the domain C, residues 38–46 make a
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short anti-parallel b sheet; residues 26–30 are also in a
b sheet conformation, but the corresponding strand comes
from the protease.
Although domains N and C possess similar disulfide pat-
terns and secondary structure topologies, the structures
are quite different because of different arrangements of
disulfide bridges. The N-terminal part is described as a
Cys1-loop1-Cys2-loop2-Cys3-loop3-Cys4 motif with differ-
ent lengths of the three loops. Disulfide bridges Cys6–
Cys17 and Cys11–Cys22 form a central core which is deco-
rated by loops. As in many other protease inhibitors [19],
the hydrophobic core normally found in globular proteins
is absent. The rigidity and the maintenance of a defined
3D structure is achieved by the disulfide bridges. Never-
theless, hydrophobic interactions play a role in the proper
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Figure 1
sA-weighted (Fo–Fc) omit map calculated in
the resolution range 8.0–2.4 Å using
calculated phases from the final model. The
electron density within a 3 Å sphere around
each atom from residues 28–33 and 47–50 is
displayed at a contour-level of 2.5s. Atoms
are shown in standard colors.
Figure 2
The overall structure of hirustasin. (a) Ribbon diagram of hirustasin.
The N-terminal and C-terminal parts are shown in different colors. The
atom labels for the five disulfide bridges are given. The P1 residue
Arg30 is indicated in the top right corner. (b) Stereo plot of the entire
hirustasin chain. Numbers refer to cysteine residues and sulfur atoms
are marked by bullets. The figure was generated using the program
MOLSCRIPT [46].
folding of domain C. The disulfide bridges Cys29–Cys48
and Cys33–Cys50 from domain C form a ring-like struc-
ture, and the space inside the ring is filled by the side
chains of Ile31 and Leu37. The ring also contains the
primary binding loop that is present in many other serine
protease inhibitors [20]. The disulfide bridge Cys24/
Cys44 links the b sheet that flanks the ring to the N-ter-
minal extension of the primary binding loop. Hydrogen
bonds between mainchain atoms are restricted to the sec-
ondary structural elements.
The interface between domains N and C is created by
residues 12–15 and residues 40–46, respectively, and the
sidechains of the amino acids are involved in the majority
of the interface contacts. The sidechains of Ala14 and
Tyr46 make hydrophobic interactions and hydrogen bonds
are found between Ser12, Ala14, Gln15, Asp40 and Asn42.
Within domain C, His28 ND1 and Asn25 ND2 interact
with Tyr46 O and Val27 O, respectively. In domain N, a
hydrogen bond is formed between Gln15 OE1 and Ser12
N (Fig. 2b).
Structural similarities
Hirustasin shows remarkable sequence homology with
antistasin, ghilanten and guamerin [4,21]. The alignment
shown in Figure 3 indicates that all cysteines are conserved
and it can be anticipated that these molecules fold into
similar 3D structures. The structure of hirustasin pre-
sented here, is the first 3D description of a member of this
inhibitor family. As antistasin and ghilanten seem to com-
prise two domains, both of which have a structure similar
to hirustasin, the overall structure of these inhibitors might
be subdivided into four domains. However, sequence com-
parisons of small, cysteine-rich molecules alone must be
treated with care. Decorsin and hirustasin, for example,
show 26% sequence identity, and five cysteines of decorsin
match perfectly with cysteines from hirustasin (data not
shown); however, the sequence alignment differs signifi-
cantly from the structural alignment in which only two of
the three disulfide bridges are conserved (Fig. 4). 
A comparison of the entire hirustasin structure with a non-
redundant subset of the Brookhaven protein data base
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Figure 3
Sequence alignment of hirustasin, guamerin
and the two domains of antistasin and
ghilanten (labeled I and II). Conserved
residues, the P1 residue and the 10 cysteines
are emphasized by yellow, brown and green
bars, respectively. At the top, the
connectivities of the disulfide bridges as they
are observed in hirustasin are indicated.
                              5         10        15            20     
 25          30        35        40        45        50        55
C N - E V H C R I R C K Y G L K K D E N G C E Y P C S C A K A S Q
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C S - G V R C R V H C P H G F Q R S R Y G C E F - C K C R L
C P - E V R C R M Y C S H G F Q R S R Y G C E V - C R C R T
C K I D I N C R K T C P N G L K R D K L G C E Y - C E C R P K R K L I P R L S
C K I D I N C R K T C P N G L K R D K L G C E Y - C E C K P K R K L V P R L S
Hirustasin            T Q G N T C G G E T C S A A Q V C - - L K G K C V
Guamerin          E D T H G L T C G E A T C S P A Q V C - - L N N E C A
Antistasin  I     E G P F G P G C E E A G C P E G S A C N I I T D R C T
Ghilanten   I     E G P F R P G C E E A G C P E G S A C N I I T D R C T
Antistasin  II    E - P M K A T C D I S E C P E G M M C S R L T N K C D
Ghilanten   II    E - P M K A T C D I S E C P E G M M C S R L T N K C D
Figure 4
Superposition of the Ca atoms of the
N-terminal part of hirustasin (residues 5–23,
black lines), decorsin (residues 16–39, red
lines), cardiotoxin (residues 2–39, green) and
cellobiohydrolase (residues 7–36, blue lines).
The two disulfide-bridges crosslinking the
three loops are shown as a ball-and-stick
model. The superposition was calculated with
the program SUPERIMPOSE [23] and
generated with the program MOLSCRIPT [46].
[22,23] showed no significant similarity with any of the
tested structures. After subdividing the hirustasin structure
into the two domains, domain C was shown to be unrelated
to any of the structures in the database. Therefore, domain
C represents a novel structural motif for cysteine-rich pro-
teins. The comparison also revealed that domain N is
structurally related to cardiotoxin, neurotoxin-I, fasciculin
1, the extracellular region of human complement regula-
tory protein CD59, the C-terminal domain of cellobiohy-
drolase I, and decorsin [2,24–28]. As it has already been
reported that hirudin [29] is similar to decorsin [2], and
that potato carboxypeptidase A inhibitor (CPI) [30] and
the trypsin inhibitor from squash seeds (CMTI-I) [31] are
similar to the C-terminal domain of cellobiohydrolase I
[28], these structures were included in the comparison
(Table 1). They vary in lengths between 29 (CMTI-I) and
77 residues (CD59), but possess the same abab pattern
with an orientation of disulfide bridges identical to that
present in the N-terminal part of hirustasin (Fig. 4). All the
listed proteins contain additional residues either at the
N terminus (decorsin and hirudin) or at the C terminus
(hirustasin, cardiotoxin, neurotoxin-I, fasciculin 1, CD59,
CPI, CMTI-I and cellobiohydrolase I) of the Cys1-loop1-
Cys2-loop2-Cys3-loop3-Cys4 motif. The N- and C-terminal
extensions are often crosslinked to the consensus motif 
by additional disulfide bridges. The similarities between
CD59 and snake venom toxins, between cellobiohydrolase
I, CPI and CMTI-I, and between decorsin and hirudin
have been described previously [2,27,28,31]. 
Although the lengths of the three loops between the disul-
fide bridges vary between 5 and 21 residues, the relative
orientations of the four cysteine residues are conserved.
The average Ca distance for a pairwise least squares
superposition is approximately 0.6Å for the four cysteine
Ca atoms. The consensus motif of the 10 structures is a
left-handed helical turn in which the subsequent repeats
are crosslinked by two disulfide bridges. Domain N of
hirustasin is the most compact structure in any of the
structures listed in Table 1. Within this group the three
loops have average lengths of 9, 6 and 12 residues, respec-
tively, with loop 1 and loop 3 being significantly more vari-
able in length than loop 2. All proteins listed in Table 1
are inhibitors, except for the C-terminal domain of cel-
lobiohydrolase. As domain N of hirustasin is not involved
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Table 1
Equivalent cysteine residues, loop lengths and cysteine Ca distances in proteins that have the abab consensus motif.
Protein Disulfide a Disulfide b Length of†
PDB code* Cys1 Cys3 Cys2 Cys4 Loop 1 loop 2 Loop 3 DCa‡ (Å)
Hirustasin 6 17 11 22 5 6 5 –
Cardiotoxin 1TGX 3 21 14 38 11 7 17 0.68
Neurotoxin-I 1NTN 3 21 14 42 11 7 21 0.69
Fasciculin 1 1FAS 3 22 17 39 14 5 17 0.38
CD59 1ERG 3 26 19 39 16 7 13 0.76
Cellobiohydrolase I 2CBH 8 25 19 35 11 6 10 0.65
Carboxypeptidase A inhibitor 4CPA 12 27 18 34 6 9 7 0.47
Cucurbita maxima trypsin inhibitor 1PPE 10 22 16 28 6 6 6 0.46
Hirudin 1HIC 16 28 22 39 6 6 11 0.50
Decorsin 1DEC 17 27 22 38 5 5 11 0.50
Average 9 6 12 0.56
(s) (3.8) (1.1) (5.0) (0.12)
*The entry codes for the Brookhaven Protein Database. †Length of loop
gives the number of residues between Cys1–Cys2 (loop 1), Cys2–Cys3
(loop 2) and Cys3–Cys4 (loop 3), including one cysteine. ‡Rms
deviation between the specified Ca atoms from Cys1, Cys2, Cys3 and
Cys4 superimposed onto Cys6, Cys11, Cys17 and Cys22 from
hirustasin.
Figure 5
Molecular surface of kallikrein colored according to the electrostatic
potential. Red and blue indicate negative and positive potentials,
respectively. Hirustasin is shown as a tube. The disulfide bridges and
the residues in the primary binding loop are indicated as stick models.
The figure was generated with the program GRASP [47].
in inhibiting tissue kallikrein, and because of the striking
structural similarity to other cysteine-rich proteins, it is very
probable that domain N has an additional function. Obvi-
ously, although these structures exhibit a similar motif, the
interactions with the target enzymes are mapped to differ-
ent parts of the structures.
Enzyme–inhibitor complex
Hirustasin binds in the active site pocket of kallikrein
which is formed by residues 39–42, 57–58, 190–196 and
214–218. As in many other serine proteases, the active site
is located in the cleft between the two kallikrein domains
[20]. Interactions between the inhibitor and the protease
are restricted to hirustasin domain C, particularly to the
primary binding loop (residues 26–33). As hirustasin has an
elongated shape and the primary binding loop is located at
one of its corners, domain N of hirustasin is pointing in the
direction of residues 169–172 of the enzyme (Figs 5,6).
The interface between hirustasin and kallikrein covers an
area of 940Å2 thus comprising 26% of the surface of hirus-
tasin. Binding of the inhibitor benefits from the opposite
electrostatic potentials in the active site of the protease and
on the surface of the inhibitor. Hirustasin carries a net load
of three positive charges that exert a positive potential
around the primary binding loop. In the complex, this area
matches onto an area of negative potential in the active site
of the protease (Fig. 5). This negative potential arises from
Asp189 and Asp194, the only charged residues not located
on the surface of the molecule. The sidechain of Asp194 is
close to the active site and forms an internal salt bridge
with the N terminus of the protease. Asp189 is located at
the bottom of the P1 pocket: The closest distance between
Asp189 and the inhibitor is 3.5Å (Asp189 OD1–Arg30 NH2).
The scissile bond between Arg30 and Ile31 of hirustasin 
is sandwiched between the sidechains of Met192 and
258 Structure 1997, Vol 5 No 2
Figure 6
The hirustasin–kallikrein complex. (a) Stereo
plot of the complex between hirustasin
(magenta) and kallikrein (light blue). The
mainchain is depicted as a tube. Some
kallikrein residues at the interface and
residues P4–P2′ from hirustasin are indicated.
(b) Superposition of the kallikrein(dark-
blue)–aprotinin(red) [16] and kallikrein (light-
blue)–hirustasin(magenta) complexes based
on the kallikrein residues. Sidechains are
color-coded. Residues with yellow and khaki
carbon atoms belong to the
kallikrein–hirustasin and kallikrein–aprotinin
complexes, respectively.
Ser195. The distance between Ser195 OG and Arg30 C is
rather short for a non-bonding interaction (2.8 Å); never-
theless, the electron density implies a planar rather than a
tetrahedral configuration at Arg30 C, indicating that the
scissile bond is not attacked by Ser195 OG. The carbonyl
oxygen is pointing into the oxyanion hole and forms
hydrogen bonds with Ser195 N and Gly193 N (Table 2).
His57, Asp102 and Ser195 comprise the catalytic triad of
kallikrein. The side chain of His57 forms hydrogen bonds
with the sidechains of Ser195 and Asp102 (Ser195 OG–
His57 NE2, 2.7Å; His57 ND1–Asp102 OD2, 2.9Å). His57
and Asp102 polarize the sidechain of Ser195 for nucle-
ophilic attack at Asp30 C. In the complex with hirustasin,
these residues are shielded from solvent by the inhibitor
disulfide bridge Cys29–Cys48 and by Phe94 and Leu95A
from the protease.
Most of the polar interactions between the inhibitor and
the protease are formed by Arg30 which fits into the P1
pocket (Figs 5,6a). All polar atoms of this residue are recog-
nized either directly by the protease or by water molecules
(Arg30 NE–Wat131–Trp141 O). As already observed in the
kallikrein–aprotinin complex [16], the residues preceding
the scissile bond are extensively recognized by the pro-
tease. Residues 26–30 of hirustasin and residues 214–218 
of kallikrein form an antiparallel b sheet. The sidechain 
of Glu26 (equivalent to P5) forms a salt bridge with the
sidechain of His217 on the kallikrein surface. The P1′ and
P2′ residues Ile31 and Arg32 are bound between loops
39–41 and 169–198 of kallikrein. The guanidinium group of
Arg32 is aligned parallel to the benzene ring of Phe153. As
the guanidinium group is probably positively charged, it
can interact with the p orbitals from the aromatic sidechain.
Interactions between positively charged ions and aromatic
groups are known to be relatively strong [32]. The sec-
ondary binding loop (residues 44–50) of hirustasin is 4–5Å
away from the active site and does not interact directly with
the protease. Only the sidechain of Glu45 forms a water-
mediated interaction with the protease.
Hydrophobic interactions seem to play an important role
for the recognition of hirustasin (Fig. 6a). The sidechain 
of Met192 from kallikrein packs against the hydropho-
bic ring of hirustasin formed by the disulfide bridges
Cys29–Cys48 and Cys33–Cys50, and the sidechains of
Leu37 and His28 (P3). Residues Trp215, His172, Pro173
and Asp174 of kallikrein create a cavity that accommo-
dates the sidechain of Val27 (P4) of hirustasin. The size
and the hydrophobicity of this cavity favor the binding of a
small hydrophobic sidechain.
As already observed in the comparison between the
uncomplexed kallikrein structure with the kallikrein–apro-
tinin complex [15,16], the bulky disulfide bridge in the 
P2 position of hirustasin forces the sidechain of Tyr99 of
kallikrein to move away from its position. This movement
is accompanied by a general reorganization of the preced-
ing loop region (residues 95–99), which is also involved in
a crystal contact.
Comparison with related enzyme–inhibitor complexes
The crystal structure of the kallikrein–aprotinin complex
has been solved at 2.5Å resolution [16]. The structure of
kallikrein in complex with aprotinin is very similar to the
structure of kallikrein in complex with hirustasin (rms devi-
ation Ca=0.58Å). In the hirustasin–kallikrein complex, the
most significant difference is observed for residues 169–
174 which contribute to the pocket that recognizes the P4
valine. Asp174 has moved 1Å away from the inhibitor to
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Table 2
Hydrogen bonds in the hirustasin–kallikrein and aprotinin–kallikrein binding sites.
Hirustasin–kallikrein Aprotinin–kallikrein
Atom in kallikrein Atom in hirustasin Distance (Å) Atom in aprotinin Distance (Å)
Gln A41 O Arg I32 N 3.2 Arg 17 N 2.7
Asp B189 OD1 Arg I30 NH2 3.5 – –
His B217 O Arg I30 NH2 2.8 – –
Asp B189 OD2 Arg I30 NH1 3.7 Lys 15 NZ 3.4
Thr B190 OG1 Arg I30 NH1 3.0 Lys 15 NZ 2.7
Thr B190 O Arg I30 NH1 3.0 Lys 15 NZ 2.7
Ser B226 OG Arg I30 NH1 3.3 Lys 15 NZ 2.9
Gly B193 N Arg I30 O 2.9 Lys 15 O 2.8
Asp B194 N Arg I30 O 3.4 Lys 15 O 3.2
Ser B195 N Arg I30 O 3.1 Lys 15 O 2.9
Ser B214 O Arg I30 N 3.0 Lys 15 N 2.9
Gly B216 N His I28 O 3.0 Pro 13 O 2.7
Gly B216 O His I28 N 2.8 – –
His B217 NE2 Glu I26 OE2 3.0 – –
Thr B218 N Glu I26 O 3.0 – –
Tyr B99 OH – – Arg39 NE 2.8
provide sufficient space for the P4 valine. Residues 171–
173 move in the opposite direction and close off the P4
pocket from the solvent. The largest shift is seen for
His172, the Ca of which moves 4Å towards the inhibitor.
In the structure of the uncomplexed kallikrein [15], this
loop adopts a conformation similar to that in the complex
with hirustasin. This difference indicates the ability of loop
169–174 to adapt its conformation to the substrate or
inhibitor. In the aprotinin complex, the P4 pocket is not
occupied because the aprotinin mainchain makes a sharp
turn after Pro13, away from the enzyme (Fig. 6b). In apro-
tinin, the primary binding loop contains recognition 
sites P2′–P3, but in hirustasin the antiparallel b-sheet is
extended at the N-terminal end by two residues (P4,
Val27; P5, Glu26). 
In hirustasin, the P1 residue is an arginine, but in apro-
tinin it is a lysine. Although the arginine in hirustasin is
longer than the lysine in aprotinin, it cannot get closer to
Asp189 at the bottom of the binding pocket, most proba-
bly because of the size of the guanidinium-group and its
ability to form additional hydrogen bonds. Arg30 NH1
from hirustasin matches perfectly onto Lys15 NZ from
aprotinin and forms a slightly longer hydrogen bond with
the protease. Arg30 NH2 forms additional hydrogen bonds
with His217 O and Asp189 OD1 (Table 2). Most of the
sidechain conformations in kallikrein are similar in the two
complexes. Striking differences are observed for the side
chain of Met192. In the complex with hirustasin, Met192
CE is lying in a hydrophobic pocket formed by the
inhibitor. This movement is supported by the different 
P1 sidechain. In the complex with aprotinin, Met192 CE
points towards Lys15 CE. Due to the bulky guanidinium-
group in hirustasin, Met192 CE can no longer be accom-
modated in this position. 
Figure 7 shows a schematic superposition of hirustasin and
aprotinin. As in many other protease inhibitors, the overall
structures of the inhibitors are totally unrelated, but the
mainchain conformations of the primary binding loops are
identical (reviewed in [20]). In hirustasin, residues 28–32,
which are equivalent to the P3–P2′ sites, match perfectly
onto residues 13–17 from aprotinin. Residues in P3–P1
adopt a b-sheet conformation and form similar hydrogen
bonds with the protease (Table 2). Among these residues,
only arginine at P2′ and cysteine at P2 are identical. The
interactions between the guanidinium group from the argi-
nine in P2′ (Arg32 in hirustasin, Arg17 in aprotinin) and
the benzene ring of Phe151 from kallikrein are conserved
in both structures. The cysteine residue in P2 is involved
in a disulfide bridge with the secondary binding loop
(Cys29–Cys48 in hirustasin, Cys14–Cys38 in aprotinin).
Interestingly, and in contrast to antistasin and ghilanten,
hirustasin does not inhibit factor Xa. A docking study based
on the structure of the uncomplexed human factor Xa [33]
superimposed onto the kallikrein structure revealed that
most of the interactions responsible for correct binding
could be formed by factor Xa as well. Hirustasin residues
that form sidechain-specific interactions with kallikrein are
P5, P4, P1 and P2′. From the alignment shown in Figure 3,
it is evident that in antistasin and ghilanten P1 is always an
arginine and P4 is either a valine or an isoleucine. Except
for domain 1 of antistasin, there is always a negatively
charged residue in P5. The greatest sequence variability in
the primary binding loops is observed for P2′. Indeed, only
hirustasin contains an arginine that is able to interact with
the benzene sidechain of Phe151. As factor Xa contains no
aromatic residue at this position, the interaction between
Arg32 and Phe151 is specific for the recognition of tissue
kallikrein by hirustasin. A similar interaction is also found
in the complex of aprotinin with kallikrein [16] and with
trypsin [34]. The relevance of an arginine at P2′ is also sup-
ported by the observation that wild-type aprotinin is a very
weak inhibitor for factor Xa [35].
Biological implications
Hirustasin acts as a potent inhibitor of tissue kallikrein
and has a potential medical application in those diseases
in which the tissue kallikrein–kinin system or a tissue
kallikrein-related protease plays a major role.  Kallidin or
lysyl-bradykinin belong to the kinin class of biologically
or pharmacologically highly potent tissue hormones, and
are released from their natural target substrate, the
kininogens, specifically by tissue kallikreins. Kinins bind
to their receptors on specific target cells and exert a broad
variety of biological activities, such as vasodilatation,
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Figure 7
Schematic superposition of hirustasin (bold line) with aprotinin (gray
surface) similar to Figure 6b. Two disulfide bridges from the C-terminal
part that are conserved and absent in the two molecules are sketched
in solid and broken lines, respectively. The hydrophobic region is
striped. Residues in P3′, P2′, P1, P2, P4 and P5 are labeled. The P1
and P4 pockets in kallikrein are indicated.
blood pressure reduction, smooth muscle relaxation or
contraction, pain and inflammation. Kinin generation is
primarily determined by the activity and availability of
kallikrein, because the level of kininogen is not the rate-
limiting factor. Kallikrein levels are controlled by the rate
of proenzyme synthesis and activation, as well as by inhi-
bition and elimination of the kallikrein–inhibitor com-
plexes. The transcription of tissue kallikreins is subjected
to regulation by a number of hormones and transcription
factors. At the post-translational level, the activity and
metabolism of kallikreins are modulated by endoge-
nous kallikrein-binding proteins. The human glandular
kallikrein-1 is very similar to the prostate-specific antigen
(PSA), which is the most sensitive marker available 
for monitoring prostate cancer progression and response
to therapy. PSA, which does not liberate kinins from
kininogens, seems to have biological activities involved in
tumor growth and metastasis [36]. The human tissue
kallikrein-1 probably has an additional  physiological role
in the prostate, in seminal fluid or at metastatic sites. Ele-
vated levels of tissue kallikrein have been found in a
human colon carcinoma cell line and in human breast
cancer cells [37, 38]. 
The structure of the hirustasin–kallikrein complex pre-
sented here reveals that this inhibitor differs from the
other known members of various inhibitor families in its
three-dimensional (3D) structure and disulfide-bridging
pattern. On the basis of sequence identity and the con-
servation of the disulfide-bridging pattern, it is likely that
a new class of leech-derived protease inhibitors, includ-
ing antistasin, guamerin and ghilanten, have a 3D struc-
ture similar to hirustasin. As these molecules all have
medical applications, the structural information can be
used for the rational design of low molecular weight
inhibitors.
Hirustasin has a compact structure that is subdivided
into two domains. Although both domains show a
similar pattern of cysteine residues, the exact orienta-
tion of disulfide bridges is different. As hirustasin lacks 
a hydrophobic core, the disulfide bridges maintain a
defined 3D structure and serve as a scaffold for the
primary binding loop that interacts with the protease.
The primary binding loop adopts a canonical conforma-
tion that is found in many other protease inhibitors. The
protease recognizes this loop as an antiparallel b sheet,
using sidechain-specific interactions that involve residues
P5, P4, P1 and P2′ of the inhibitor. Although the P1
arginine contributes most of the hydrogen bonds between
the protease and the inhibitor, the P2′ arginine seems 
to be responsible for the discrimination between tissue
kallikrein and factor Xa. 
The N-terminal domain of hirustasin does not interact
with the protease but it is structurally similar to a number
of other proteins such as cardiotoxin, neurotoxin-I, fasci-
culin 1, the extracellular region of human complement
regulatory protein CD59, the C-terminal domain of cel-
lobiohydrolase I, carboxypeptidase A inhibitor, trypsin
inhibitor from squash seeds, hirudin and decorsin. The
consensus motif can be described as a left-handed helical
turn that is connected by at least two disulfide bridges.
The lengths of the three loops connecting the cysteine
residues differ between 5 and 21 residues.
Materials and methods
Crystallization 
Pure recombinant hirustasin was purified as described by Di Marco et al.
[21]. One aliquot (50 ml) of hirustasin was mixed with a 50 ml aliquot of
kallikrein to final kallikrein and hirustasin concentrations of 0.50 mM and
0.85mM, respectively, in 20mM Tris-HCl, pH8.0. Crystals were grown
using the ‘hanging drop’ method. The crystallizing solution consisted of
23% polyethyleneglycol (PEG) 2000 monomethyl ether, 0.18 M ammo-
nium sulfate and 3.5% dioxane in 0.1 M sodium acetate buffer, pH 4.6.
Crystals to a maximum size of 1 × 0.5 × 0.1mm3 were obtained after 2–3
days at room temperature. These crystals were stable only for one week,
after which they started to change in morphology and birefringence. The
1:1 ratio of hirustasin and kallikrein in the crystals was confirmed by
SDS-PAGE and by RP-HPLC (data not shown).
Data collection
For data collection, crystals were transferred from the crystallization drop
to a stabilizing solution consisting of 34% polyethylenglycol (PEG) 2000
monomethyl ether and 0.2 M ammonium sulfate, in 0.1 M sodium acetate
buffer, pH4.6. Two native data sets were collected at room tempera-
ture on similar image-plate systems (Mar Research), one mounted at the
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Figure 8
Harker section (w = 1/2) of the native Patterson map, calculated for the
resolution range 20.0–2.4 Å (u, horizontal; v, vertical). The symmetry-
related peaks at (1/2, 1/3, 1/2) and (1/2, 2/3, 1/2) possess 50.5% of
the origin peak height.
Swiss/Norwegian beam-line at the European Synchrotron Radiation
Facility (ESRF, Grenoble) and the other on an in-house FR591 rotating
anode system (Nonius). Statistics of the individual and the combined
data sets are given in Table 3. Both data sets were processed with
MARXDS [39] and combined using MARSCALE. Only the first 50° of
data were useful because the crystals suffered strong radiation damage.
Because of the radiation damage and high mosaicity, the data were of
poor quality as indicated by a Rsym of 12.6%. The average intensity of
the diffraction pattern was weaker in the direction of the c* axis than in
the a*/b* plane. Because of the absence of the odd reflections along h, k
and l, we assigned the orthorhombic space-group P212121 with unit-cell
dimensions of a=69.4Å, b=86.0Å, c=116.9Å, a=b= g =90°. Visual
inspection of the combined data set indicated that all reflections with
k=3n: h+ l ≠ 2n were either weak or absent.
Structure solution and refinement
The structure was solved by molecular replacement (program AMoRe)
[40] using the 2.05 Å crystal structure of porcine kallikrein (Brookhaven
accession code: 2PKA) as a search model. We assumed two hirus-
tasin–kallikrein complexes per asymmetric unit with a packing parame-
ter of 2.77 Å3 Da–1. However, the cross-rotation functions calculated
for various resolution ranges, showed only one significant peak. Using
data between 8.0 and 3.0 Å resolution and a Patterson sphere of 20 Å,
an 11s peak was found for the rotation a = 112.21°, b = 31.25° and
g = 167.40°. The absence of a second solution was in agreement with
the absence of any significant peaks in the self-rotation function and
with the results of a native Patterson map which showed one signifi-
cant peak at (1/2, 1/3, 1/2) (Fig. 8).
Preliminary translation functions calculated in space-group P212121
yielded promising correlation and Rf values, but the packing of the second
molecule was always very poor. As the translation vectors observed in the
native Patterson map can generate pseudo-extinction patterns along a*
and c*, we examined the alternative space-group P21212. The translation
function for the first molecule gave a significant solution for a=0.2510,
b=0.3205 and c=0.4631 (r=48.9%, Rf =54.4%, 10.0–3.0Å resolu-
tion). For the second molecule, we found two conspicuous solutions of
nearly equivalent height (1. solution: a=0.7514, b=0.6526, c=0.9635,
r=67.2%, Rf =47.5%; 2. solution: a=0.7513, b=0.9882, c=0.9631,
r=66.9%, Rf =48.3%, 10.0–3.0Å resolution). These two solutions dif-
fered only in Db=0.33. Because the Fo–Fc map showed clearly the bound
inhibitor, we took this as an indication for the correctness of solution 1.
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Figure 9
Average B factors (continuous lines) and real-
space correlation values (broken lines) for the
two hirustasin chains (thick lines, residues
I5–I52; thin lines, residues J5–J52) are shown
plotted over the residue number.
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Table 3
Statistics of data sets.
Data set 1 Data set 2 Combined data sets
All data Last shell
Unit cell parameters (Å) a = 69.19, b = 86.02, a = 69.57, b = 85.97, – –
c = 116.63 c = 117.23 – –
Wavelength (Å) 1.54 0.875 – –
Detector distance (mm) 120 200 – –
Frame / exposure (sec–1) 0.5° / 360 1.0° / 180 – –
Resolution (Å) 24.5–2.4 24.5–2.4 24.5–2.4 2.45–2.40
Rsym (%)* 12.5 12.8 12.6 47.4
Observations 52 768 42 129 96 170 4 989
Unique reflections – – 27 511 1 623
Completeness (%) – – 97.9 98.6
Percentage [I]≥2s (%) – – 56.8 32.9
Multiplicity – – 3.5 3.1
*Rsym =Shkl
S
i
|Ihkl,i– < Ihkl > | / Shkl Si |Ihkl,i|.
The initial R-factor for the correctly positioned search-model was 50.2%
for all data between 7.0 and 2.4Å resolution.
The twofold averaged sA-weighted electron-density maps (program AVE
[41] and SIGMAA [42]) were sufficiently clear to trace the hirustasin
main chain and to assign the disulfide bridges. We subsequently refined
the model to a working R-factor of 31.2% (free R factor= 42.2%) using
X-PLOR [43] and O [44]. Because of the anisotropy of the data set, we
applied overall anisotropic B factor refinement [45]. Individual inspection
of the two complexes showed good electron density for the first mol-
ecule, but very poor density for the second. This led us to check whether
we could solve the structure by molecular replacement in space-group
P21212 with a=116.9Å, b=86.0Å, c=69.4Å, a =b = g =90° using the
pre-refined complex. The cross-rotation function yielded a 13.8s peak at
a= 66.00°, b= 154.67° and g= 93.50° (8.0–3.5Å resolution and a Pat-
terson sphere of 20Å). The translation function clearly showed solutions
for the first complex at a =0.2506, b=0.2623 and c=0.000 (r=43.4%,
Rf =57.2%, 8.0–3.5Å resolution) and for the second complex at
a=0.7507, b=0.5964 and c=0.5020 (r=86.6%, Rf =30.3%, 8.0–3.5
Å resolution). The R factor for the correctly positioned search-model was
34.2% (8.0–2.4Å resolution). It was subsequently reduced to 20.5%
(free R factor=31.1%) for all data between 8.0 and 2.4 Å. The rms devi-
ations for bond lengths and angles are 0.011 Å and 1.72°, respectively.
During refinement, the second complex was transferred into the asym-
metric unit of the first complex by applying the symmetry operator (-x, -y,
z) and the translation (1,1,0). The final structure of the hirustasin–
kallikrein complex contains two copies of residues 16–247 from the 
protease and residues 5–52 from the inhibitor. All mainchain dihedral
angles fall into allowed regions of the Ramachandran diagram. The
average B factor for all 4584 atoms is 46.2 Å2. Among them there are
304 water molecules with an average B factor of 53.6Å2. The average
B factors of the two kallikrein molecules are 37.9 Å2 (41.8Å2) and of 
the two hirustasin molecules 61.7 Å2 (88.1Å2), respectively. The average
B factors and real-space correlation values [44] for hirustasin are plotted
over the residue number in Figure 9. 
Database searches
To check if the structure of hirustasin is similar to any known structure,
it was superimposed on all structures from a non-redundant subset of
the Brookhaven Protein Database. This database contained 721 struc-
tures, all of which have less than 35% sequence identity [22]. For the
automatic calculation of optimal superpositions the program SUPERIM-
POSE [23] was used. Residues 5–23 and 23–52 of hirustasin were
checked individually. Significant structural similarity was indicated only
for the N-terminal part by best-fit values between 3.9s and 2.8s.
Accession numbers
The coordinates of the hirustasin–kallikrein complex have been deposited
at the Brookhaven Protein Databank (ID code 1H1A).
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